Tag
Montana's expanded right-to-try law now allows any biotech company to sell experimental drugs to consumers after a review, with the first clinics expected later this year. The law, driven by longevity advocates, raises concerns about oversight and safety.
As US measles cases hit a 35-year high, biotech companies like Invivyd are developing monoclonal antibody treatments for measles, though they are years away from availability.
With measles cases reaching a 35-year high in the US due to declining vaccination rates, biotech companies and researchers are developing monoclonal antibody treatments for the disease, though these therapies may take years to become available.
This MIT Technology Review newsletter covers a breakthrough in organ preservation using supercooling to -4°C without ice, enabling days-long storage for transplantation, and China's push to develop domestic chips to replace US technology. It also includes other tech news on space data centers, AI safety, and FDA peptide approvals.
In a new interview, Dr. Derya Unutmaz predicts that longevity escape velocity will arrive within 8–10 years, potentially extending lifespan by 50 years, and that cancer will be 100% curable in less than a decade.
Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, a significant increase from its previous $10.2 billion valuation. The round is not yet confirmed, and final terms are unknown.
OpenAI researcher Miles Wang is leaving to launch an AI drug discovery startup, with talks to raise $200 million at a $2 billion valuation led by Lightspeed.
A roundup of tech news including a proposal to limit sperm donor children, developments in AI world models, and Apple suing OpenAI over trade secrets.
This edition of The Download covers the impact of AI chip profits on South Korea's dating market, a device that could enable eye transplants, and other tech news.
The article discusses heuristics for lab robotics, covering different types of robots (box vs. arm), the cost-benefit of automating protocols, and the future directions in translation, hardware, and intelligence layers. It draws on insights from multiple experts in the field.
Anthropic launched Claude Science, a flagship product for scientific research that can autonomously carry out tasks in computational biology and drug development, signaling a major bet on AI for science.
Conception announces a milestone in creating early human eggs from stem cells using lab-grown mini-ovaries, advancing in vitro gametogenesis toward potential fertility treatments.
Intercept, a $500 million philanthropic initiative, aims to use new platform technologies and air cleaning to reduce or eliminate respiratory infections like colds and influenza, citing the significant health and economic burdens they cause.
Nicole Fitzgerald announces Tacit Labs, a new applied research lab at the intersection of AI and biology, with investment from Every.
The FDA's rejection of UniQure's gene therapy AMT-130 for Huntington's disease has been overturned after the ouster of Trump officials, including regulator Vinay Prasad, who had demanded sham surgeries for a placebo control.
This newsletter covers two major tech stories: a biotech company's first human trial of 'reprogramming' cells to reverse aging, and the growing field of interoception research. It also notes SpaceX's record-breaking IPO.
TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab 2.0, Eli Lilly's collaborative AI/ML drug discovery platform.
LifeBioSciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic restoration drug candidate for optic neuropathies, marking a milestone in the development of therapies for vision impairment.
Life Biosciences has dosed its first patient with ER-100, a cellular rejuvenation therapy aiming to reverse age-related sight loss, in a first-ever human clinical trial approved by the FDA.
This WIRED security news roundup covers Meta's dormant face-recognition code, xAI's legal battle over deepfake nudes, Google's anti-scam Android feature, and a highlight on crypto-funded Chinese labs selling peptides.